The Rohatyn Group has invested in Amethyst Radiotherapy

Abolon was the exclusive adviser to The Rohatyn Group (“TRG”), an emerging markets focused asset management firm, on its investment in Amethyst Radiotherapy, obtaining co-control of the Company alongside the two co-founders. Amethyst is one of the largest operators of radiotherapy clinics in Europe and provides radiotherapy treatment for most types of common cancers. The transaction was announced yesterday.
Amethyst operates centres across France, Romania, Italy, Poland and Austria, treating over 10,000 patients annually. TRG’s investment will be used to accelerate the growth of the Company across Europe through the roll-up of clinics, the development of greenfield centres and outsourcing partnerships with hospitals.
Radiation therapy (also called radiotherapy) is a cancer treatment that uses high doses of radiation to kill cancer cells and/or to slow down their growth by damaging their DNA. Abolon served TRG with a dedicated team of its specialised advisers, building on numerous projects in the broader radiotherapy & radiology space during recent years.